Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy study of BMS-986165 in systemic lupus erythematosus
MOH_2019-12-08_008542Phase 2Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of deucravacitinib in systemic lupus erythematosus (SLE) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Safety and tolerability of BMS-986165 over 108 weeks. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
deucravacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2019-12-08_008542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-12-08_008542.